Deals Of The Week: Cephalon/Mesoblast; GSK/MeiRui; Geron/Angiochem…
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Geron Restructuring Sours Investors As Company Bets On Cancer
The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.
Pfizer Watchers Try To Read New CEO's Next Moves
Pfizer, Inc.,'s abrupt management shake-up, announced Dec. 5, comes almost a year to the day its key drug Lipitor goes off patent. Whether the timing of the changes was a coincidence or the result of accumulating pressures, the patent expiration date of November 2011 is a marker for new CEO Ian Read and portends additional changes at the world's largest drug manufacturer.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”